Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AN2 Therapeutics, Inc. (ANTX)
NASDAQ:ANTX
ANTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.87 - $3.88
Previous CloseN/A
Volume42.38K
Average Volume (3M)131.40K
Market Cap
$34.06M
Enterprise Value-$61.50M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Mar 27, 2025EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.04
Shares Outstanding29,878,890
10 Day Avg. Volume170,768
30 Day Avg. Volume131,403
Standard Deviation0.36
R-Squared0.00039
Alpha-0.00160
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda1.40
Forecast
1Y Price Target
$3.50Price Target Upside204.35% Upside
Rating ConsensusHold
Number of Analyst Covering2
---
AN2 Therapeutics, Inc. News
PremiumCompany Announcements
AN2 Therapeutics Promotes Joshua Eizen to Key Roles
---
Bulls Say, Bears Say
Bulls Say
Drug ApprovalDr. Winthrop believes that the FDA will likely accept QoL-B respiratory as an efficacy endpoint, which could benefit AN2's drug approval process.
Market ValuationShares are viewed as extremely undervalued if Phase 3 results can corroborate Phase 2 findings.
Bears Say
Clinical EfficacyEpetraborole did not show a difference in culture conversion relative to placebo in Phase 2, causing shares to tumble and a shift in focus to other pipeline programs.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ANTX FAQ
What was AN2 Therapeutics, Inc.’s price range in the past 12 months?
AN2 Therapeutics, Inc. lowest stock price was $0.87 and its highest was $3.88 in the past 12 months.
What is AN2 Therapeutics, Inc.’s market cap?
AN2 Therapeutics, Inc.’s market cap is $34.06M.
When is AN2 Therapeutics, Inc.’s upcoming earnings report date?
AN2 Therapeutics, Inc.’s upcoming earnings report date is Mar 27, 2025 which is in 35 days.
How were AN2 Therapeutics, Inc.’s earnings last quarter?
AN2 Therapeutics, Inc. released its earnings results on Nov 13, 2024. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.45 by $0.02.
Is AN2 Therapeutics, Inc. overvalued?
According to Wall Street analysts AN2 Therapeutics, Inc.’s price is currently Undervalued.
Does AN2 Therapeutics, Inc. pay dividends?
AN2 Therapeutics, Inc. does not currently pay dividends.
What is AN2 Therapeutics, Inc.’s EPS estimate?
AN2 Therapeutics, Inc.’s EPS estimate is -0.27.
How many shares outstanding does AN2 Therapeutics, Inc. have?
AN2 Therapeutics, Inc. has 29,878,890 shares outstanding.
What happened to AN2 Therapeutics, Inc.’s price movement after its last earnings report?
AN2 Therapeutics, Inc. reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.45. Following the earnings report the stock price went down -0.99%.
Which hedge fund is a major shareholder of AN2 Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ANTX
---
AN2 Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.50 (204.35% Upside)
$3.50 (204.35% Upside)
Insider Transactions
Bought Shares
Worth $415.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.40%
12-Months-Change
Fundamentals
Return on Equity
-53.56%
Trailing 12-Months
Asset Growth
-36.49%
Trailing 12-Months
Company Description
AN2 Therapeutics, Inc.
AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.
---
ANTX Stock 12 Month Forecast
Average Price Target
$3.50
▲(204.35% Upside)
Technical Analysis
Best Analysts Covering ANTX
1 Year
1 Year Success Rate
3/9 ratings generated profit
1 Year Average Return
-28.29%
reiterated a buy rating 23 hours ago
Copying Roy Buchanan's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -28.29% per trade.
---